Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains-Reference-Cited by-同舟云学术

Generation and evaluation of protease inhibitor-resistant SARS-CoV-2 strains

Published:2024-02 Issue: Volume:222 Page:105814
ISSN:0166-3542
Container-title:Antiviral Research
language:en
Short-container-title:Antiviral Research

Author:

Bouzidi Hawa Sophia,Driouich Jean-Sélim^ORCID,Klitting Raphaëlle^ORCID,Bernadin Ornéllie^ORCID,Piorkowski Géraldine,Amaral Rayane,Fraisse Laurent,Mowbray Charles E.,Scandale Ivan,Escudié Fanny^ORCID,Chatelain Eric^ORCID,de Lamballerie Xavier,Nougairède Antoine,Touret Franck^ORCID

Publisher

Elsevier BV

Reference44 articles.

1. Remdesivir for the treatment of Covid-19 — final report;Beigel;N. Engl. J. Med.,2020

2. Permissive secondary mutations enable the Evolution of Influenza Oseltamivir resistance;Bloom;Science,2010

3. Preclinical characterization of an intravenous coronavirus 3CL protease inhibitor for the potential treatment of COVID19;Boras;Nat. Commun.,2021

4. Favipiravir antiviral efficacy against SARS-CoV-2 in a hamster model;Driouich;Nat. Commun.,2021

5. Pre-clinical evaluation of antiviral activity of nitazoxanide against SARS-CoV-2;Driouich;EBioMedicine,2022

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. N-acylbenzimidazoles as selective Acylators of the catalytic cystein of the coronavirus 3CL protease;European Journal of Medicinal Chemistry;2024-10

2. SARS-CoV-2 Mpro inhibitor identification using a cellular gain-of-signal assay for high-throughput screening;SLAS Discovery;2024-09

3. Efficacy of late-onset antiviral treatment in immunocompromised hosts with persistent SARS-CoV-2 infection;Journal of Virology;2024-08-29

4. Efficacy of late-onset antiviral treatment in immune-compromised hosts with persistent SARS-CoV-2 infection;2024-05-23

5. SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs;Cell Chemical Biology;2024-04